- /
- Supported exchanges
- / US
- / LBTSF.PINK
Almirall S.A (LBTSF PINK) stock market data APIs
Almirall S.A Financial Data Overview
Almirall, S.A. operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising Psoriasis, atopic dermatitis, acne, actinic keratosis, onychomycosis, androgenic alopecia, oncodermatology, and orphan indications, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, nervous, and respiratory system; dermatologicals; genito urinary system and sex hormones; immunostimulants; metabolism; and systematic hormonal preparations. It has a multi-target partnership with Etherna to research and develop mRNA-based therapies for medical dermatology. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Almirall S.A data using free add-ons & libraries
Get Almirall S.A Fundamental Data
Almirall S.A Fundamental data includes:
- Net Revenue: 1 054 M
- EBITDA: 179 M
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2022-07-24
- EPS/Forecast: 0.05
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Almirall S.A News
New
Almirall (BME:ALM): Is the Recent Share Price Momentum Justified by Its Current Valuation?
Almirall (BME:ALM) shares have quietly advanced this month, gaining 7% over the past four weeks. Investors might be paying closer attention to the company’s fundamentals as the company shows steady ...
Can Almirall’s Strong 2025 Rally Continue After Positive Dermatology Pipeline Developments?
If you are wondering whether now is the right moment to make a move on Almirall, you are definitely not alone. Over the last year, Almirall’s stock has turned quite a few heads, climbing a remarkabl...
Absci Corporation (ABSI) Secures $64M Financing to Drive AI Drug Discovery Through 2028
In this article, we will be taking a look at the Top 10 AI-Powered Biotech Stocks to Buy Now. Absci Corporation is one of them. Absci Corporation (NASDAQ:ABSI), founded in 2018 and headquartered in S...
Almirall Presents Long‑Term Results from First Real‑World Dermatology Study Using WHO‑5 Well‑Being Index as Primary Endpoint in the treatment of Psoriasis at EADV 2025
Results of the POSITIVE study assessing the treatment with tildrakizumab showed sustained improvements in skin clearance, psychological well-being, and improved partner quality of life in adults with ...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.